LSTA

Marea Therapeutics, a subsidiary of Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE), said data from the Phase 2b TYDAL study of its lead candidate MAR001 will be presented in a late-breaking science session at the American Heart Association Scientific Sessions 2026 in Chicago.  MAR001 is an experimental antibody that blocks a protein called ANGPTL4, which helps fat tissue work properly, with the goal of lowering triglycerides and improving how the body handles fat.

SOUTH SAN FRANCISCO and LIBERTY CORNER, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Marea Therapeutics, Inc. (“Marea”), a subsidiary of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that data from the Phase 2b TYDAL study of MAR001, a potential first-in-class monoclonal antibody targeting angiopoietin-like protein 4 (ANGPTL4), will be presented in a late-breaking science session at the American Heart Association (AHA) Scientific Sessions 2026, taking place November 6-9, 2026, in Chicago, Illinois.

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has acquired Marea Therapeutics, a clinical-stage biotech developing next-generation medicines for cardioendocrine diseases.  The companies also entered a private placement financing agreement expected to raise approximately $225 million in gross proceeds.

Combined company to focus on developing first-in-class next-generation medicines for cardioendocrine diseases Marea has multiple late-stage clinical product candidates: MAR001/005 for severe hypertriglyceridemia (sHTG) currently in Phase 2b and MAR002 for the treatment of acromegaly which is advancing to a Phase 2 study Concurrent financing of $225 million from leading life sciences investors and other institutional investors projected to fund operations into 2028 LIBERTY CORNER, N.J., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company, today announced that it has acquired Marea Therapeutics, Inc. (“Marea”), a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases.

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said on Tuesday it has taken decisive action following the termination of its merger agreement with Kuva Labs and its subsidiary Kuva Acquisition Corp, filing suit to protect stockholder interests and moving swiftly to strengthen its financial position. The clinical-stage pharmaceutical company, which develops therapies for advanced solid tumors, filed the lawsuit in the Delaware Court of Chancery, alleging Kuva breached the merger agreement dated March 6, 2026.

Lisata has filed suit against Kuva Labs Inc. and its subsidiary seeking, among other things, damages for the benefit of its stockholders

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating Lisata Therapeutics, Inc. (NASDAQ: LSTA) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws.

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - June 15, 2026) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Lisata Therapeutics, Inc. ("Lisata Therapeutics" or the "Company") (NASDAQ - LSTA) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Kuva Labs, Inc. ("Kuva") for $4.00 per share in cash plus two non-tradeable contingent value rights (CVRs), payable as follows: (1) $1.00 per share, in cash, within 12 months of the date on which rights to certepetide in the Greater China region revert to Lisata from Qilu Pharmaceutical; and (2) $1.00 per share, in cash, upon the filing of an NDA or similar registration document by Kuva for approval to commercialize certepetide in any indication in any jurisdiction. The investigation concerns whether the Lisata Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether the deal consideration provides fair value to the Company's shareholders.

Lisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) has agreed to be acquired by privately held Kuva Labs Inc. for $4 per share in cash, plus a contingent value right worth up to an additional $3.00 per share tied to drug development milestones.

Lisata stockholders to receive $4.00 per share in cash at closing, plus one non-tradeable contingent value right, which represents the contractual right to receive two contingent cash payments of up to an aggregate of $3.00 per share, subject to achievement of specified milestones